Screening for preclinical and prodromal Alzheimer disease clinical trials: predicting NIA‐AA research framework ATN category by leveraging neuropsychiatric symptoms
Zahinoor Ismail, Rebeca Leon, Dylan X. Guan, Eric E. Smith · 2025
Read Screening for preclinical and prodromal Alzheimer disease clinical trials: predicting NIA‐AA research framework ATN category by leveraging neuropsychiatric symptoms by Zahinoor Ismail, Rebeca Leon, Dylan X. Guan, Eric E. Smith (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11714620.txt.
Description
Zahinoor Ismail and three co-authors test a cheap way to spot early Alzheimer's disease for trials, in a 2025 paper. New drugs work best early, but the spinal fluid tests that confirm the illness cost much and hurt. The team asks whether a lasting change in conduct, called mild behavioral impairment, can flag who is likely to test positive.
They studied 984 older adults without dementia from a shared US data set. People with the lasting conduct change had more than twice the odds of positive results for the two hallmark proteins of the illness. Brief or passing symptoms showed no such link. The authors say screening for the conduct change could help trial teams pick whom to test first.
Catalog record
| CREATOR | Zahinoor Ismail, Rebeca Leon, Dylan X. Guan, Eric E. Smith |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |